Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan
· Delayed Price · Currency is TWD 177.50
+4.50 (2.60%)
Apr 2, 2025, 1:30 PM CST
Lumosa Therapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 235.49 | 425.25 | 516.85 | 840.32 | 898.64 | Upgrade
|
| Short-Term Investments | 1,117 | 419.06 | 667.67 | 589.89 | 372.26 | Upgrade
|
| Trading Asset Securities | - | - | - | 21.89 | - | Upgrade
|
| Cash & Short-Term Investments | 1,353 | 844.31 | 1,185 | 1,452 | 1,271 | Upgrade
|
| Cash Growth | 60.23% | -28.72% | -18.43% | 14.26% | 103.34% | Upgrade
|
| Accounts Receivable | 20.63 | 12 | 14 | 9.69 | 13.84 | Upgrade
|
| Other Receivables | 19.16 | 18.13 | 17.98 | 17.01 | 16.38 | Upgrade
|
| Receivables | 39.79 | 30.14 | 31.98 | 26.7 | 30.22 | Upgrade
|
| Inventory | 97.78 | 103.91 | 108.68 | 82.39 | 31.78 | Upgrade
|
| Prepaid Expenses | 46.64 | 65.66 | 60.88 | 59.17 | 13.65 | Upgrade
|
| Other Current Assets | 0.02 | 0.02 | - | 0.13 | 0.02 | Upgrade
|
| Total Current Assets | 1,537 | 1,044 | 1,386 | 1,620 | 1,347 | Upgrade
|
| Property, Plant & Equipment | 19.68 | 27.53 | 7.66 | 13 | 19.5 | Upgrade
|
| Long-Term Investments | 575.42 | 583.79 | 464.72 | 671.32 | 246.72 | Upgrade
|
| Goodwill | - | - | - | - | 78.49 | Upgrade
|
| Other Intangible Assets | 0.49 | 0.6 | 26.93 | 43.57 | 92.72 | Upgrade
|
| Other Long-Term Assets | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | Upgrade
|
| Total Assets | 2,133 | 1,656 | 1,886 | 2,349 | 1,784 | Upgrade
|
| Accounts Payable | 1.42 | 1.49 | 12.25 | 14.5 | 0.03 | Upgrade
|
| Accrued Expenses | 36.7 | 54.41 | 33.62 | 43.26 | 28.68 | Upgrade
|
| Current Portion of Leases | 4.2 | 4.49 | 4.33 | 5.4 | 5.83 | Upgrade
|
| Current Unearned Revenue | 3.04 | 3.04 | 6.88 | 4.68 | 0.32 | Upgrade
|
| Other Current Liabilities | 155.83 | 156.14 | 158.28 | 156.18 | 155.65 | Upgrade
|
| Total Current Liabilities | 201.18 | 219.58 | 215.36 | 224.03 | 190.5 | Upgrade
|
| Long-Term Leases | 4.28 | 8.12 | 0.36 | 6.08 | 11.13 | Upgrade
|
| Total Liabilities | 205.46 | 227.69 | 215.72 | 230.11 | 201.63 | Upgrade
|
| Common Stock | 1,689 | 1,650 | 1,631 | 1,632 | 1,474 | Upgrade
|
| Additional Paid-In Capital | 2,223 | 1,363 | 1,268 | 1,271 | 963.36 | Upgrade
|
| Retained Earnings | -1,919 | -1,494 | -1,256 | -761.44 | -857.38 | Upgrade
|
| Comprehensive Income & Other | -81.59 | -117.45 | -13.53 | -22.98 | 2.96 | Upgrade
|
| Total Common Equity | 1,912 | 1,401 | 1,630 | 2,119 | 1,583 | Upgrade
|
| Minority Interest | 15.84 | 27.89 | 40.18 | - | - | Upgrade
|
| Shareholders' Equity | 1,928 | 1,429 | 1,670 | 2,119 | 1,583 | Upgrade
|
| Total Liabilities & Equity | 2,133 | 1,656 | 1,886 | 2,349 | 1,784 | Upgrade
|
| Total Debt | 8.48 | 12.61 | 4.69 | 11.49 | 16.95 | Upgrade
|
| Net Cash (Debt) | 1,344 | 831.7 | 1,180 | 1,441 | 1,254 | Upgrade
|
| Net Cash Growth | 61.64% | -29.51% | -18.10% | 14.89% | 104.46% | Upgrade
|
| Net Cash Per Share | 8.22 | 5.12 | 7.26 | 9.55 | 10.38 | Upgrade
|
| Filing Date Shares Outstanding | 168.9 | 164.97 | 163.1 | 163.15 | 147.37 | Upgrade
|
| Total Common Shares Outstanding | 168.9 | 164.97 | 163.1 | 163.15 | 147.37 | Upgrade
|
| Working Capital | 1,336 | 824.46 | 1,171 | 1,396 | 1,156 | Upgrade
|
| Book Value Per Share | 11.32 | 8.49 | 9.99 | 12.99 | 10.74 | Upgrade
|
| Tangible Book Value | 1,911 | 1,400 | 1,603 | 2,075 | 1,411 | Upgrade
|
| Tangible Book Value Per Share | 11.32 | 8.49 | 9.83 | 12.72 | 9.58 | Upgrade
|
| Machinery | 41.95 | 41.5 | 31.82 | 29.53 | 29.53 | Upgrade
|
| Leasehold Improvements | 3.21 | 3.21 | - | - | 0.24 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.